Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 269


Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.

Tanioka M, Fan C, Parker JS, Hoadley KA, Hu Z, Li Y, Hyslop TM, Pitcher BN, Soloway MG, Spears PA, Henry LN, Tolaney S, Dang CT, Krop IE, Harris LN, Berry DA, Mardis ER, Winer EP, Hudis CA, Carey LA, Perou CM.

Clin Cancer Res. 2018 Jul 23. doi: 10.1158/1078-0432.CCR-17-3431. [Epub ahead of print]


Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study.

Li D, McCall LM, Hahn OM, Hudis CA, Cohen HJ, Muss HB, Jatoi A, Lafky JM, Ballman KV, Winer EP, Tripathy D, Schneider B, Barry W, Dickler MN, Hurria A.

Breast Cancer Res Treat. 2018 Sep;171(2):325-334. doi: 10.1007/s10549-018-4828-5. Epub 2018 May 22.


Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer.

Morris PG, Rota S, Cadoo K, Zamora S, Patil S, D'Andrea G, Gilewski T, Bromberg J, Dang C, Dickler M, Modi S, Seidman AD, Sklarin N, Norton L, Hudis CA, Fornier MN.

Clin Breast Cancer. 2018 Oct;18(5):387-394. doi: 10.1016/j.clbc.2018.03.010. Epub 2018 Mar 15.


The Impact of Obesity on Breast Cancer.

Argolo DF, Hudis CA, Iyengar NM.

Curr Oncol Rep. 2018 Apr 11;20(6):47. doi: 10.1007/s11912-018-0688-8. Review.


A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease.

Gucalp A, Zhou XK, Cook ED, Garber JE, Crew KD, Nangia JR, Bhardwaj P, Giri DD, Elemento O, Verma A, Wang H, Lee JJ, Vornik LA, Mays C, Weber D, Sepeda V, O'Kane H, Krasne M, Williams S, Morris PG, Heckman-Stoddard BM, Dunn BK, Hudis CA, Brown PH, Dannenberg AJ.

Cancer Prev Res (Phila). 2018 Apr;11(4):203-214. doi: 10.1158/1940-6207.CAPR-17-0354. Epub 2018 Feb 16.


Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier Detection.

Morikawa A, Wang R, Patil S, Diab A, Yang J, Hudis CA, McArthur HL, Beal K, Seidman AD.

Clin Breast Cancer. 2018 Oct;18(5):353-361. doi: 10.1016/j.clbc.2017.12.009. Epub 2017 Dec 21.


Effects of Rapid Weight Loss on Systemic and Adipose Tissue Inflammation and Metabolism in Obese Postmenopausal Women.

Alemán JO, Iyengar NM, Walker JM, Milne GL, Da Rosa JC, Liang Y, Giri DD, Zhou XK, Pollak MN, Hudis CA, Breslow JL, Holt PR, Dannenberg AJ.

J Endocr Soc. 2017 Apr 25;1(6):625-637. doi: 10.1210/js.2017-00020. eCollection 2017 Jun 1.


Adiposity, Inflammation, and Breast Cancer Pathogenesis in Asian Women.

Iyengar NM, Chen IC, Zhou XK, Giri DD, Falcone DJ, Winston LA, Wang H, Williams S, Lu YS, Hsueh TH, Cheng AL, Hudis CA, Lin CH, Dannenberg AJ.

Cancer Prev Res (Phila). 2018 Apr;11(4):227-236. doi: 10.1158/1940-6207.CAPR-17-0283. Epub 2017 Dec 8.


Correlative imaging reveals physiochemical heterogeneity of microcalcifications in human breast carcinomas.

Kunitake JAMR, Choi S, Nguyen KX, Lee MM, He F, Sudilovsky D, Morris PG, Jochelson MS, Hudis CA, Muller DA, Fratzl P, Fischbach C, Masic A, Estroff LA.

J Struct Biol. 2018 Apr;202(1):25-34. doi: 10.1016/j.jsb.2017.12.002. Epub 2017 Dec 6.


Leptin regulation of the p53-HIF1α/PKM2-aromatase axis in breast adipose stromal cells: a novel mechanism for the obesity-breast cancer link.

Zahid H, Subbaramaiah K, Iyengar NM, Zhou XK, Chen IC, Bhardwaj P, Gucalp A, Morrow M, Hudis CA, Dannenberg AJ, Brown KA.

Int J Obes (Lond). 2018 Apr;42(4):711-720. doi: 10.1038/ijo.2017.273. Epub 2017 Nov 6.


American Society of Clinical Oncology Summit on Addressing Obesity Through Multidisciplinary Provider Collaboration: Key Findings and Recommendations for Action.

Ligibel JA, Alfano CM, Hershman DL, Merrill JK, Basen-Engquist K, Bloomgarden ZT, Demark-Wahnefried W, Dixon S, Hassink SG, Jakicic JM, Morton JM, Okwuosa TM, Powell-Wiley TM, Rothberg AE, Stephens M, Streett SE, Wild RA, Westman EA, Williams RJ, Wollins DS, Hudis CA.

Obesity (Silver Spring). 2017 Nov;25 Suppl 2:S34-S39. doi: 10.1002/oby.21987.


RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer.

Baselga J, Zamagni C, Gómez P, Bermejo B, Nagai SE, Melichar B, Chan A, Mángel L, Bergh J, Costa F, Gómez HL, Gradishar WJ, Hudis CA, Rapoport BL, Roché H, Maeda P, Huang L, Meinhardt G, Zhang J, Schwartzberg LS.

Clin Breast Cancer. 2017 Dec;17(8):585-594.e4. doi: 10.1016/j.clbc.2017.05.006. Epub 2017 May 22.


Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.

Yu AF, Mukku RB, Verma S, Liu JE, Oeffinger KC, Steingart RM, Hudis CA, Dang CT.

Breast Cancer Res Treat. 2017 Nov;166(1):241-247. doi: 10.1007/s10549-017-4362-x. Epub 2017 Jul 14.


Periprostatic adipose inflammation is associated with high-grade prostate cancer.

Gucalp A, Iyengar NM, Zhou XK, Giri DD, Falcone DJ, Wang H, Williams S, Krasne MD, Yaghnam I, Kunzel B, Morris PG, Jones LW, Pollak M, Laudone VP, Hudis CA, Scher HI, Scardino PT, Eastham JA, Dannenberg AJ.

Prostate Cancer Prostatic Dis. 2017 Dec;20(4):418-423. doi: 10.1038/pcan.2017.31. Epub 2017 Jun 27.


Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score.

Mariotti V, Page DB, Davydov O, Hans D, Hudis CA, Patil S, Kunte S, Girotra M, Farooki A, Fornier MN.

J Bone Oncol. 2016 Oct 18;7:32-37. doi: 10.1016/j.jbo.2016.10.004. eCollection 2017 Jun.


MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer.

Dickler MN, Tolaney SM, Rugo HS, Cortés J, Diéras V, Patt D, Wildiers H, Hudis CA, O'Shaughnessy J, Zamora E, Yardley DA, Frenzel M, Koustenis A, Baselga J.

Clin Cancer Res. 2017 Sep 1;23(17):5218-5224. doi: 10.1158/1078-0432.CCR-17-0754. Epub 2017 May 22.


Untapped Potential of Observational Research to Inform Clinical Decision Making: American Society of Clinical Oncology Research Statement.

Visvanathan K, Levit LA, Raghavan D, Hudis CA, Wong S, Dueck A, Lyman GH.

J Clin Oncol. 2017 Jun 1;35(16):1845-1854. doi: 10.1200/JCO.2017.72.6414. Epub 2017 Mar 30.


Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.

Yu AF, Singh JC, Wang R, Liu JE, Eaton A, Oeffinger KC, Steingart RM, Hudis CA, Dang CT.

Oncologist. 2017 Jun;22(6):642-647. doi: 10.1634/theoncologist.2016-0406. Epub 2017 Mar 24.


Menopause Is a Determinant of Breast Aromatase Expression and Its Associations With BMI, Inflammation, and Systemic Markers.

Brown KA, Iyengar NM, Zhou XK, Gucalp A, Subbaramaiah K, Wang H, Giri DD, Morrow M, Falcone DJ, Wendel NK, Winston LA, Pollak M, Dierickx A, Hudis CA, Dannenberg AJ.

J Clin Endocrinol Metab. 2017 May 1;102(5):1692-1701. doi: 10.1210/jc.2016-3606.


Metabolic Obesity, Adipose Inflammation and Elevated Breast Aromatase in Women with Normal Body Mass Index.

Iyengar NM, Brown KA, Zhou XK, Gucalp A, Subbaramaiah K, Giri DD, Zahid H, Bhardwaj P, Wendel NK, Falcone DJ, Wang H, Williams S, Pollak M, Morrow M, Hudis CA, Dannenberg AJ.

Cancer Prev Res (Phila). 2017 Apr;10(4):235-243. doi: 10.1158/1940-6207.CAPR-16-0314. Epub 2017 Mar 7.


The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials.

Roviello G, Bachelot T, Hudis CA, Curigliano G, Reynolds AR, Petrioli R, Generali D.

Eur J Cancer. 2017 Apr;75:245-258. doi: 10.1016/j.ejca.2017.01.026. Epub 2017 Feb 24. Review.


Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience.

Singh JC, Mamtani A, Barrio A, Morrow M, Sugarman S, Jones LW, Yu AF, Argolo D, Smyth LM, Modi S, Schweber S, Boafo C, Patil S, Norton L, Baselga J, Hudis CA, Dang C.

Oncologist. 2017 Feb;22(2):139-143. doi: 10.1634/theoncologist.2016-0268. Epub 2017 Feb 6.


Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).

Ollila DW, Cirrincione CT, Berry DA, Carey LA, Sikov WM, Hudis CA, Winer EP, Golshan M.

J Am Coll Surg. 2017 Apr;224(4):688-694. doi: 10.1016/j.jamcollsurg.2016.12.036. Epub 2017 Jan 13.


Reply to L.B. Marks et al.

Recht A, Comen EA, Fine RE, Fleming GF, Hardenbergh PH, Ho AY, Hudis CA, Hwang ES, Kirshner JJ, Morrow M, Salerno KE, Sledge GW Jr, Solin LJ, Spears PA, Whelan TJ, Somerfield MR, Edge SB.

J Clin Oncol. 2017 Apr 10;35(11):1258-1259. doi: 10.1200/JCO.2016.71.3966. Epub 2017 Jan 9. No abstract available.


Docosahexaenoic Acid Supplementation is Not Anti-Inflammatory in Adipose Tissue of Healthy Obese Postmenopausal Women.

Holt PR, Alemán JO, Walker JM, Jiang CS, Liang Y, de Rosa JC, Giri DD, Iyengar NM, Milne GL, Hudis CA, Breslow JL.

Int J Nutr. 2017;1(4):31-49. doi: 10.14302/issn.2379-7835.ijn-17-1636. Epub 2017 Jul 21.


Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527.

Freedman RA, Foster JC, Seisler DK, Lafky JM, Muss HB, Cohen HJ, Mandelblatt J, Winer EP, Hudis CA, Partridge AH, Carey LA, Cirrincione C, Moreno-Aspitia A, Kimmick G, Jatoi A, Hurria A.

J Clin Oncol. 2017 Feb;35(4):421-431. doi: 10.1200/JCO.2016.69.4182. Epub 2016 Dec 19.


Estimating the OncotypeDX score: validation of an inexpensive estimation tool.

Eaton AA, Pesce CE, Murphy JO, Stempel MM, Patil SM, Brogi E, Hudis CA, El-Tamer M.

Breast Cancer Res Treat. 2017 Feb;161(3):435-441. doi: 10.1007/s10549-016-4069-4. Epub 2016 Dec 7.


Obesity and Cancer Mechanisms: Tumor Microenvironment and Inflammation.

Iyengar NM, Gucalp A, Dannenberg AJ, Hudis CA.

J Clin Oncol. 2016 Dec 10;34(35):4270-4276. Epub 2016 Nov 7. Review.


Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511).

Freedman RA, Seisler DK, Foster JC, Sloan JA, Lafky JM, Kimmick GG, Hurria A, Cohen HJ, Winer EP, Hudis CA, Partridge AH, Carey LA, Jatoi A, Klepin HD, Citron M, Berry DA, Shulman LN, Buzdar AU, Suman VJ, Muss HB.

Breast Cancer Res Treat. 2017 Jan;161(2):363-373. doi: 10.1007/s10549-016-4051-1. Epub 2016 Nov 19.


Research needs in breast cancer.

Cardoso F, Harbeck N, Barrios CH, Bergh J, Cortés J, El Saghir N, Francis PA, Hudis CA, Ohno S, Partridge AH, Sledge GW, Smith IE, Gelmon KA.

Ann Oncol. 2017 Feb 1;28(2):208-217. doi: 10.1093/annonc/mdw571.


A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling.

McArthur HL, Diab A, Page DB, Yuan J, Solomon SB, Sacchini V, Comstock C, Durack JC, Maybody M, Sung J, Ginsberg A, Wong P, Barlas A, Dong Z, Zhao C, Blum B, Patil S, Neville D, Comen EA, Morris EA, Kotin A, Brogi E, Wen YH, Morrow M, Lacouture ME, Sharma P, Allison JP, Hudis CA, Wolchok JD, Norton L.

Clin Cancer Res. 2016 Dec 1;22(23):5729-5737. Epub 2016 Aug 26.


Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update.

Recht A, Comen EA, Fine RE, Fleming GF, Hardenbergh PH, Ho AY, Hudis CA, Hwang ES, Kirshner JJ, Morrow M, Salerno KE, Sledge GW Jr, Solin LJ, Spears PA, Whelan TJ, Somerfield MR, Edge SB.

Pract Radiat Oncol. 2016 Nov - Dec;6(6):e219-e234. doi: 10.1016/j.prro.2016.08.009. Epub 2016 Sep 19. Review.


Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update.

Recht A, Comen EA, Fine RE, Fleming GF, Hardenbergh PH, Ho AY, Hudis CA, Hwang ES, Kirshner JJ, Morrow M, Salerno KE, Sledge GW Jr, Solin LJ, Spears PA, Whelan TJ, Somerfield MR, Edge SB.

J Clin Oncol. 2016 Dec 20;34(36):4431-4442. doi: 10.1200/JCO.2016.69.1188. Epub 2016 Sep 30. Review.


Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update.

Recht A, Comen EA, Fine RE, Fleming GF, Hardenbergh PH, Ho AY, Hudis CA, Hwang ES, Kirshner JJ, Morrow M, Salerno KE, Sledge GW Jr, Solin LJ, Spears PA, Whelan TJ, Somerfield MR, Edge SB.

Ann Surg Oncol. 2017 Jan;24(1):38-51. doi: 10.1245/s10434-016-5558-8. Epub 2016 Sep 19.


Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.

Cadoo KA, Morris PG, Cowell EP, Patil S, Hudis CA, McArthur HL.

Clin Breast Cancer. 2016 Dec;16(6):487-493. doi: 10.1016/j.clbc.2016.07.013. Epub 2016 Aug 1.


Increasing Precision in Adjuvant Therapy for Breast Cancer.

Hudis CA, Dickler M.

N Engl J Med. 2016 Aug 25;375(8):790-1. doi: 10.1056/NEJMe1607947. No abstract available.


Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.

Wen HY, Krystel-Whittemore M, Patil S, Pareja F, Bowser ZL, Dickler MN, Norton L, Morrow M, Hudis CA, Brogi E.

Cancer. 2017 Jan 1;123(1):131-137. doi: 10.1002/cncr.30271. Epub 2016 Aug 15.


White adipose tissue inflammation and cancer-specific survival in patients with squamous cell carcinoma of the oral tongue.

Iyengar NM, Ghossein RA, Morris LG, Zhou XK, Kochhar A, Morris PG, Pfister DG, Patel SG, Boyle JO, Hudis CA, Dannenberg AJ.

Cancer. 2016 Dec 15;122(24):3794-3802. doi: 10.1002/cncr.30251. Epub 2016 Aug 10.


Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study.

Smyth LM, Iyengar NM, Chen MF, Popper SM, Patil S, Wasserheit-Lieblich C, Argolo DF, Singh JC, Chandarlapaty S, Sugarman SM, Comen EA, Drullinsky PR, Traina TA, Troso-Sandoval T, Baselga J, Norton L, Hudis CA, Dang CT.

Breast Cancer Res Treat. 2016 Jul;158(1):91-97. doi: 10.1007/s10549-016-3851-7. Epub 2016 Jun 15.


Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received.

Schnipper LE, Davidson NE, Wollins DS, Blayney DW, Dicker AP, Ganz PA, Hoverman JR, Langdon R, Lyman GH, Meropol NJ, Mulvey T, Newcomer L, Peppercorn J, Polite B, Raghavan D, Rossi G, Saltz L, Schrag D, Smith TJ, Yu PP, Hudis CA, Vose JM, Schilsky RL.

J Clin Oncol. 2016 Aug 20;34(24):2925-34. doi: 10.1200/JCO.2016.68.2518. Epub 2016 May 31. No abstract available.


Copper-64 trastuzumab PET imaging: a reproducibility study.

Carrasquillo JA, Morris PG, Humm JL, Smith-Jones PM, Beylergil V, Akhurst T, O'Donoghue JA, Ruan S, Modi S, Hudis CA, Larson SM.

Q J Nucl Med Mol Imaging. 2016 May 12. [Epub ahead of print]


Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance).

Dickler MN, Barry WT, Cirrincione CT, Ellis MJ, Moynahan ME, Innocenti F, Hurria A, Rugo HS, Lake DE, Hahn O, Schneider BP, Tripathy D, Carey LA, Winer EP, Hudis CA.

J Clin Oncol. 2016 Aug 1;34(22):2602-9. doi: 10.1200/JCO.2015.66.1595. Epub 2016 May 2.


Erratum to: Obesity and Cancer: Concepts and Challenges.

Argolo DF, Iyengar NM, Hudis CA.

Indian J Surg Oncol. 2015 Dec;6(4):399. doi: 10.1007/s13193-015-0484-y. Epub 2015 Dec 22.


Obesity and Cancer: Concepts and Challenges.

Argolo DF, Iyengar NM, Hudis CA.

Indian J Surg Oncol. 2015 Dec;6(4):390-8. doi: 10.1007/s13193-015-0483-z. Epub 2015 Nov 23. Erratum in: Indian J Surg Oncol. 2015 Dec;6(4):399.


Exocytosis of macrophage lysosomes leads to digestion of apoptotic adipocytes and foam cell formation.

Haka AS, Barbosa-Lorenzi VC, Lee HJ, Falcone DJ, Hudis CA, Dannenberg AJ, Maxfield FR.

J Lipid Res. 2016 Jun;57(6):980-92. doi: 10.1194/jlr.M064089. Epub 2016 Apr 4.


Decreased gastrointestinal toxicity associated with a novel capecitabine schedule (7 days on and 7 days off): a systematic review.

Cadoo KA, Gajria D, Suh E, Patil S, Theodoulou M, Norton L, Hudis CA, Traina TA.

NPJ Breast Cancer. 2016 Mar 30;2:16006. doi: 10.1038/npjbcancer.2016.6. eCollection 2016.


Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013.

King TA, Lyman JP, Gonen M, Voci A, De Brot M, Boafo C, Sing AP, Hwang ES, Alvarado MD, Liu MC, Boughey JC, McGuire KP, Van Poznak CH, Jacobs LK, Meszoely IM, Krontiras H, Babiera GV, Norton L, Morrow M, Hudis CA.

J Clin Oncol. 2016 Jul 10;34(20):2359-65. doi: 10.1200/JCO.2015.63.1960. Epub 2016 Mar 21.


Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.

Yu AF, Manrique C, Pun S, Liu JE, Mara E, Fleisher M, Patil S, Jones LW, Steingart RM, Hudis CA, Dang CT.

Oncologist. 2016 Apr;21(4):418-24. doi: 10.1634/theoncologist.2015-0321. Epub 2016 Mar 16.


Targeting obesity-related adipose tissue dysfunction to prevent cancer development and progression.

Gucalp A, Iyengar NM, Hudis CA, Dannenberg AJ.

Semin Oncol. 2016 Feb;43(1):154-160. doi: 10.1053/j.seminoncol.2015.09.012. Epub 2015 Sep 8. Review.


The Genomic Landscape of Male Breast Cancers.

Piscuoglio S, Ng CK, Murray MP, Guerini-Rocco E, Martelotto LG, Geyer FC, Bidard FC, Berman S, Fusco N, Sakr RA, Eberle CA, De Mattos-Arruda L, Macedo GS, Akram M, Baslan T, Hicks JB, King TA, Brogi E, Norton L, Weigelt B, Hudis CA, Reis-Filho JS.

Clin Cancer Res. 2016 Aug 15;22(16):4045-56. doi: 10.1158/1078-0432.CCR-15-2840. Epub 2016 Mar 9.

Supplemental Content

Loading ...
Support Center